Chinook Therapeutics
stock surged Monday after Swiss pharmaceutical company
Novartis
agreed to buy the biopharma company for up to $3.5 billion.
The company said it has entered into an agreement to be acquired by
Novartis
(ticker; NVS) for $40a share in cash, with a potential additional $4 a share in cash contingent on its kidney disease drug candidate atrasentan reaching certain regulatory milestones. Reaching those milestones would take the deal’s total value to $3.5 billion.
At $40 a share in cash, or a total of $3.2 billion, the upfront offer represents a 67% premium to Friday’s closing price of $23.99. The stock was trading at $37.52, up 56%, on Monday.
The deal is expected to be completed in the second half of 2023,
Chinook
(KDNY) said in a press release Monday.
“Chinook’s diversified pipeline of potentially best-in-class programs for rare, severe chronic kidney diseases will significantly expand the Novartis renal portfolio, complementing its existing pipeline,” it added.
Novartis’ American depositary receipts were down 1%.
Write to Callum Keown at callum.keown@barrons.com
Read the full article here
